Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.050 +0.020 (+1.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,472,783
Open 1.020
Bid (Size) 1.040 (10)
Ask (Size) 1.050 (88)
Prev. Close 1.030
Today's Range 1.020 - 1.055
52wk Range 0.5150 - 1.400
Shares Outstanding 257,328,085
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
From Ocugen
Via GlobeNewswire

Performance

YTD
+16.7%
+16.7%
1 Month
+1.0%
+1.0%
3 Month
+38.4%
+38.4%
6 Month
+46.3%
+46.3%
1 Year
-19.8%
-19.8%

More News

Read More
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
From Ocugen
Via GlobeNewswire
Demystifying Ocugen: Insights From 5 Analyst Reviews
Via Benzinga
Ocugen (OCGN) Q2 Revenue Jumps 20%
Via The Motley Fool
Ocugen Inc (NASDAQ:OCGN) Q2 2025 Earnings: Revenue Surges, EPS Loss Narrows
Via Chartmill
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
A Peek at Ocugen's Future Earnings
Via Benzinga
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
From Ocugen
Via GlobeNewswire
Earnings Scheduled For August 1, 2025
Via Benzinga
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
From Brodsky & Smith LLC
Via GlobeNewswire
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?
Via Benzinga
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
From Ocugen
Via GlobeNewswire
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial
Via Benzinga
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
From Ocugen
Via GlobeNewswire
Ocugen To Present at BIO International Convention 2025
From Ocugen
Via GlobeNewswire
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
From Ocugen
Via GlobeNewswire
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
From Ocugen
Via GlobeNewswire
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
The Analyst Verdict: Ocugen In The Eyes Of 5 Experts
Via Benzinga
Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish
Via Stocktwits
Topics Lawsuit
Ocugen Provides Business Update with First Quarter 2025 Financial Results
From Ocugen
Via GlobeNewswire

Frequently Asked Questions

Is Ocugen, Inc. - Common Stock publicly traded?
Yes, Ocugen, Inc. - Common Stock is publicly traded.
What exchange does Ocugen, Inc. - Common Stock trade on?
Ocugen, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ocugen, Inc. - Common Stock?
The ticker symbol for Ocugen, Inc. - Common Stock is OCGN on the Nasdaq Stock Market
What is the current price of Ocugen, Inc. - Common Stock?
The current price of Ocugen, Inc. - Common Stock is 1.050
When was Ocugen, Inc. - Common Stock last traded?
The last trade of Ocugen, Inc. - Common Stock was at 08/15/25 04:00 PM ET
What is the market capitalization of Ocugen, Inc. - Common Stock?
The market capitalization of Ocugen, Inc. - Common Stock is 270.19M
How many shares of Ocugen, Inc. - Common Stock are outstanding?
Ocugen, Inc. - Common Stock has 270M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.